DV
Dividend Vision

TSHA — Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. (TSHA)

Total return is -75.3% over the past 5.9 years, 234.9 points behind SPY at 159.6%. Its deepest 1-year drawdown was 31.1%.

TSHA is an equity stock that tracks Taysha Gene Therapies, Inc., a single-company holding rather than a diversified fund. The security does not currently pay distributions, making it unsuitable for income-focused investors seeking dividend yields. This holding appeals primarily to investors with a growth-oriented outlook who are interested in direct exposure to the gene therapy sector.

TSHA key facts

Asset type
Stock
Asset class
Equity
Inception date
09/24/2020
Distribution frequency
None
Last close
$5.95
Market cap
$1,938,709,504
Average volume
2131900.0
Beta
1.187
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.41